Rare Liver Focus GENFIT targets rare and life-threatening liver diseases with a diversified pipeline including ACLF, HE, cholangiocarcinoma, UCD, OA, and MASH diagnostics, presenting multiple partnerable assets and diagnostic tools for specialty pharma and CRO collaborations.

Clinical Momentum Recent Phase 3 readout for ELATIVE in PBC and ongoing Phase 2 programs in ACLF and cholangiocarcinoma indicate a robust clinical trajectory, offering opportunities for co-development, licensing, or milestone-based collaborations with larger biopharma seeking liver disease assets.

Strategic Partnerships Ipsen holds an 8% stake and remains a significant shareholder, signaling potential for continued co-development, co-commercialization, or strategic alliances that can facilitate market access and global distribution.

Diagnostics and Access NIS4 powered NASHnext diagnostic technology, now accessible via Labcorp OnDemand, creates channels for managed care partnerships, payer discussions, and value-based care pilots identifying at-risk MASH patients.

Global Footprint Operations across France, Switzerland, and the US with Cambridge, MA, presence enable regional BD outreach, cross-border collaborations, and multi-market pilots, supported by a public market listing and active investor communications.